Skip to content

Study · Systematic review · 2026

6 results

Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.

Chen KY, Chan HC, Chan CM

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)15 Sept 2025Cited by 8 (Europe PMC)

PMID40962119 (opens in a new tab)DOI10.1016/j.apjo.2025.100245 (opens in a new tab)PepBankPUB-40962119
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In a meta-analysis, semaglutide use was associated with a significantly increased risk of NAION compared with control medications (pooled HR 2.620).

    In plain wordsA pooled analysis linked semaglutide use to a higher risk of a rare optic nerve condition (NAION) than control medicines.

    Peptide
    Semaglutide
    Outcome
    IncreaseRisk of non-arteritic anterior ischemic optic neuropathy (NAION)
    Study

    n: not reported in source

    Comparator
    Control medications
    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    Pooled hazard ratio
    2.62
    semaglutide versus control medications
    95% CI
    1.808 to 3.795
    pooled hazard ratio

    Source sentences

    Summary
    Semaglutide use was associated with a significantly increased risk of NAION compared to control medications, with a pooled hazard ratio of 2.620 (95 % CI: 1.808-3.795, P < 0.001).
    1 context sentence
    Summary · context
    The database search yielded 3539 records, of which 10 research articles investigating the association between Semaglutide and NAION were included in this study.
  2. 02HumanSystematic reviewSafety outcome

    In the meta-analysis, the elevated NAION risk with semaglutide was time-dependent and became statistically significant after 2 years of exposure.

    In plain wordsA pooled analysis found the higher risk of NAION with semaglutide became clear only after about 2 years of use.

    Peptide
    Semaglutide
    Outcome
    IncreaseTime dependency of NAION risk
    Study

    n: not reported in source

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Risk elevation showed time-dependency, becoming statistically significant after 2 years of exposure.
    1 context sentence
    Summary · context
    The database search yielded 3539 records, of which 10 research articles investigating the association between Semaglutide and NAION were included in this study.
  3. 03HumanSystematic reviewOther

    In the meta-analysis, identified risk factors for NAION included older age, male sex, prolonged diabetes duration, elevated HbA1c, diabetic retinopathy, and obesity.

    In plain wordsA pooled analysis listed older age, male sex, long diabetes duration, high HbA1c, diabetic retinopathy and obesity as risk factors.

    Peptide
    Semaglutide
    Outcome
    Not applicableRisk factors for NAION in semaglutide users
    Study

    n: not reported in source

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Identified risk factors included older age, male sex, prolonged diabetes duration, elevated HbA1c, diabetic retinopathy, and obesity.
    1 context sentence
    Summary · context
    The database search yielded 3539 records, of which 10 research articles investigating the association between Semaglutide and NAION were included in this study.
  4. 04HumanSystematic reviewSafety outcome

    In the meta-analysis, semaglutide accounted for 86.5 % of the NAION cases reported among GLP-1 receptor agonists.

    In plain wordsA pooled analysis found semaglutide accounted for most (86.5 %) of the NAION cases reported with GLP-1 drugs.

    Peptide
    Semaglutide
    Outcome
    Not applicableShare of reported NAION cases among GLP-1 receptor agonists
    Study

    n: not reported in source

    Comparator
    Other GLP-1 receptor agonists
    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    Share of reported NAION cases
    86.5%
    semaglutide among GLP-1 receptor agonists

    Source sentences

    Summary
    Among GLP-1 receptor agonists, semaglutide accounted for 86.5 % of reported NAION cases.
    1 context sentence
    Summary · context
    The database search yielded 3539 records, of which 10 research articles investigating the association between Semaglutide and NAION were included in this study.
  5. 05HumanSystematic reviewOther

    In the meta-analysis, NAION cases presented with optic disc edema, intraretinal fluid on OCT, and crowded optic discs.

    In plain wordsA pooled analysis described the eye findings in NAION cases: swollen optic discs, fluid in the retina and crowded optic discs.

    Peptide
    Semaglutide
    Outcome
    Not applicableClinical presentation of NAION
    Study

    n: not reported in source

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Clinical presentations featured optic disc edema, intraretinal fluid on OCT, and crowded optic discs.
    1 context sentence
    Summary · context
    The database search yielded 3539 records, of which 10 research articles investigating the association between Semaglutide and NAION were included in this study.
  6. 06HumanSystematic reviewSafety outcome

    In the meta-analysis, cumulative NAION incidence rates were substantially higher in semaglutide users than in non-GLP-1 receptor agonist comparators.

    In plain wordsA pooled analysis found NAION happened more often in semaglutide users than in people on non-GLP-1 comparator drugs.

    Peptide
    Semaglutide
    Outcome
    IncreaseCumulative incidence of NAION
    Study

    n: not reported in source

    Comparator
    Non-GLP-1 receptor agonist comparators
    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cumulative incidence rates were substantially higher in semaglutide users versus non-GLP-1 receptor agonist comparators.
    1 context sentence
    Summary · context
    The database search yielded 3539 records, of which 10 research articles investigating the association between Semaglutide and NAION were included in this study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.